Clal Biotechnology Industries Ltd.
CBI
Rank in Stocks
#28747
Clal Biotechnology Industries Ltd. (CBI) operates as a venture capital and... Clal Biotechnology Industries Ltd. (CBI) operates as a venture capital and private equity firm, primarily funding innovative companies within the life sciences, medical device, biopharmaceutical, and broader biotechnology sectors. The firm is adept at investing across a comprehensive spectrum of development stages, ranging from initial incubation, seed, and startup phases, through early, emerging, mid, and late-stage ventures, including pre-clinical development, PIPEs, and growth capital financing. CBI strategically targets companies based in the United States and Israel, typically deploying between $0.5 million and $10 million into each investment. It frequently assumes the role of a lead investor and a significant shareholder, often securing a board seat within its portfolio companies. Established in July 1998, CBI utilizes the personal capital of its management team for its investments. Its primary base is in Tel Aviv, Israel, complemented by an additional office in Cambridge, Massachusetts. The firm formerly functioned as a subsidiary of Clal Industries and Investments Ltd.
Share Price
$0.06645984
Last synced: 2026-11-12
Market Cap
$9.79M
Change (1 day)
-3.41%
Change (1 year)
-35.97%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Clal Biotechnology Industries Ltd. (CBI)
Category
Healthcare
Operating Margin for Clal Biotechnology Industries Ltd. (CBI)
Operating Margin as of November 2026 TTM: -194.91%
According to Clal Biotechnology Industries Ltd.'s latest financial reports, its current operating margin (TTM) is -194.91%. At the end of 2025 the company had an operating margin of -2,205.03%.
Operating Margin history for Clal Biotechnology Industries Ltd. from 2005 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -194.91% | -91.16% |
| 2025 | -2,205.03% | 50.48% |
| 2024 | -1,465.36% | -85.03% |
| 2023 | -9,789.42% | 32.11% |
| 2022 | -7,410.00% | -78.61% |
| 2021 | -34,637.50% | -277.70% |
| 2020 | 19,492.23% | -27,752.48% |
| 2019 | -70.49% | -90.11% |
| 2018 | -712.52% | 488.91% |
| 2017 | -120.99% | -83.59% |
| 2016 | -737.46% | 3.97% |
| 2015 | -709.28% | -73.38% |
| 2014 | -2,664.20% | -38.31% |
| 2013 | -4,318.48% | 216.67% |
| 2012 | -1,363.71% | -19.93% |
| 2011 | -1,703.11% | -53.42% |
| 2010 | -3,656.45% | 41.48% |
| 2009 | -2,584.47% | -8.98% |
| 2008 | -2,839.35% | 2.40% |
| 2007 | -2,772.89% | 235.80% |
| 2006 | -825.75% | -42.62% |
| 2005 | -1,439.10% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | -99.00% |
US
|
|
| 33.87% | -100.17% |
US
|
|
| -116.04% | -99.40% |
US
|
|
| 25.57% | -100.13% |
AU
|
|
| 31.23% | -100.16% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Clal Biotechnology Industries Ltd.'s operating margin
What is Clal Biotechnology Industries Ltd.'s operating margin?
Clal Biotechnology Industries Ltd.'s operating margin is -194.91%, as of Nov 2026.
What was Clal Biotechnology Industries Ltd.'s operating margin in 2025?
In 2025, Clal Biotechnology Industries Ltd.'s operating margin was -2,205.03%, compared with -1,465.36% in 2024.
How has Clal Biotechnology Industries Ltd.'s operating margin changed since 2020?
From 2020 to 2025, Clal Biotechnology Industries Ltd.'s operating margin was highest in 2020 (19,492.23%) and lowest in 2021 (-34,637.50%).
How does Clal Biotechnology Industries Ltd.'s operating margin compare with similar companies?
Clal Biotechnology Industries Ltd.'s operating margin (-194.91%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.